The Use of RGD-K5 PET Imaging for Selecting Candidate Patients for Receiving Avastin




          Molecular imaging can play a critical role in the development and use of targeted therapies. In 2011 US FDA revoked the market approval of Avastin for treating breast cancer. Avastin is the most widely used anti-angiogenic drug, yet there is no established biomarker that can be used for selecting patients who are good candidates thus more likely to show a good response. Also, there is no appropriate method for monitoring treatment response. We have shown that one patient with a high RGD-k5 uptake responding well to Avastin, but not the other patient who had a low RGD-K5, supporting its role as a biomarker for Avastin-containing therapy.